We reviewed patient-related, disease-related, pulmonary function and survival characteristics for the entire group of patients and for those deemed to required noninvasive positive pressure ventilation (NIPPV). We separated adherence to NIPPV into four groups: 1) Non-users who elected not to use NIPPV at all, 2) non-tolerant patients who continued to use NIPPV but did not meet the criterion of 4 consecutive hours of use during sleep, 3) adherent patient who met the criterion of 4 consecutive hours of use during sleep, and 4) patients for whom adherence could not be determined due to death or loss of follow up.
to a pressure manometer. The olive was used to occlude one nostril and the maneuver conducted from residual volume with the best of several trials selected (generally three). We have always performed the maneuver with the contralateral nostril occluded, with more recent literature supporting this approach compared to the more commonly recommended open contralateral nostril approach. [1] Statistical Analysis Categorical factors were described using percentages and compared between groups with a chi-square test. Continuous measures were described with means and standard deviations and compared between groups with an ANOVA for normally distributed data, or medians and inter-quartiles and compared between groups with a Kruskal-Willis test for nonnormally distributed data. Survival analysis was compared between groups with a log-rang test.
A linear mixed model analysis was used to analyze correlations between variables with repeated measures per subject.
In an earlier model, [2] we assumed that the rate of functional decline would favorably change after NIPPV initiation and set the inflection point to that time point (i.e., b3 = 0).
Segmented nonlinear mixed effects models were used to investigate individual changes of predicted forced vital capacity (FVCP), and to assess the effect of NIPPV on the rates of change. The time variable was partitioned into two intervals, before and after the date of NIPPV initiation, and a separate line segment was fit to each interval (i.e., one for t < 0 and one for t  0). Maximization likelihood estimation with adaptive Gaussian quadrature was applied to solve the nonlinear models and estimate the model parameters.
RESULTS
Descriptive characteristics for all 507 patients are shown in Table E1 In 360 patients who died during the course of the study, the median time from the last FVCP measurement to the date of death was 4.7 months (interquartile range [IQR]: 2.0-9.1) with no significant difference in that interval between those with an ALSFRS bulbar score < 7 (5.1 IQR: 2.1-9.1) vs. > 7 (4.1 IQR:1.9-9.1) (p = 0.31).
NIPPV was deemed necessary in 419 patients through the course of the study. There were 181 adherent patients, 106 non-tolerant patients, 66 non-users, and 66 with unknown adherence. There was no significant differences in those various parameters between not tolerant patients and non-users. Similarly, for the nonlinear mixed effects models partitioned into two time segments (before and after initiation of NIPPV), there was no difference in the various parameters between the non-tolerant group and the non-user group (Table E2) . Those two groups were combined in all other analyses into a non-adherent group (172 patients) including in the main text. Descriptive characteristics for all subjects for whom NIPPV was deemed necessary are shown in Table E3 .
Modelling the course of lung function after diagnosis of ALS showed that an asymptotic model provided a good fit of the data. Specifically, a rapid decline in the FVCP around the time of NIPPV initiation was followed by a slowing the rate of lung function decline to a plateau ( Figure E1 ). Both the pre-and post-NIPPV curves fit the observed data. The post NIPPV curve was associated with a maximal decline in lung function to a plateau FVCP of 34%. In contrast, extrapolation from the pre-NIPPV data predicted a modeled FVCP plateau at the lower asymptote of 12% without NIPPV ( Figure E1 ). Although this pattern suggests a beneficial effect of NIPPV on the final FVCP, the model did not fit the observed pattern in non-adherent patients, who generally had a much higher FVCP at the lower asymptote of 38.5%, indicating that the main assumption of the model (i.e., that the inflection point is due to NIPPV initiation) was incorrect. Subsequent analyses in the main text removed the assumption that NIPPV was the reason for the inflection (b3 ≠ 0) and did not use a segmented approach.
Application of the revised model to the course of decline of percent predicted forced vital capacity (FVCP) is discussed in the main text. In this revised model, resolution of the parameters for the percent predicted forced expiratory volume in the first second (FEV 1 ) and percent predicted maximum inspiratory pressures (MIPP) are shown in Table E4 in this   supplement and Table 4 Onset to diagnosis (months) 11.0 (7.0-18) n = 501 Bulbar subset of ALSFRS 9 (6-11) n = 424 Cervical subset of ALSFRS 7 (4-9) n = 423 Pulmonary FVCP 67 (51-83) n = 497 † Percent or median (interquartile range). n is number of patients in case of an incomplete set of data. Parameters: b1: percent predicted forced expiratory volume in one second before onset of decline of lung function; b2: magnitude of decline in percent predicted forced expiratory volume in one second to the lower asymptote, represented in the model as a negative number; b3: time (months) relative to initiation of non-invasive ventilation to the mid-point between the two asymptotes, also representing the inflection point of the percent predicted forced espiratory volume in the first second; b4: a time scale factor (months) that reflects the rapidity of decline of percent predicted forced expiratory volume in the first second.
